News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
174,117 Results
Type
Article (13015)
Company Profile (24)
Press Release (161078)
Section
Business (49684)
Career Advice (611)
Deals (9240)
Drug Delivery (29)
Drug Development (28317)
Employer Resources (69)
FDA (4714)
Job Trends (3915)
News (92488)
Policy (7953)
Tag
Academia (1075)
Africa (259)
Allergies (17)
Alliances (13991)
Alzheimer's disease (371)
Approvals (4693)
Arizona (22)
Artificial intelligence (22)
Asia (12328)
Australia (2359)
Bankruptcy (67)
Best Places to Work (3137)
Biosimilars (34)
Breast cancer (17)
C2C Services and Suppliers (17403)
California (418)
Canada (184)
Cancer (140)
Career advice (509)
Cell therapy (33)
China (49)
Clinical research (23298)
Collaboration (33)
Connecticut (23)
COVID-19 (1053)
Data (101)
Diabetes (23)
Diagnostics (1569)
Diversity, equity & inclusion (28)
Drug pricing (29)
Earnings (14017)
Employer resources (63)
Europe (33767)
Events (20419)
Executive appointments (39)
FDA (4775)
Florida (51)
Funding (44)
Gene therapy (35)
Georgia (28)
GLP-1 (234)
Government (1156)
Healthcare (5407)
Hotbed/Location (106536)
Illinois (72)
Indiana (45)
Infectious disease (1060)
Inflammatory bowel disease (34)
Interviews (104)
IPO (3468)
Job creations (810)
Job search strategy (454)
Kansas (26)
Layoffs (78)
Legal (1560)
Liver cancer (18)
Lung cancer (32)
Management (23)
Manufacturing (21)
Maryland (105)
Massachusetts (231)
Medical device (3090)
Medtech (3092)
Mergers & acquisitions (5772)
Metabolic disorders (81)
Michigan (21)
Minnesota (56)
Neuroscience (423)
New Jersey (145)
New York (182)
NextGen Class of 2024 (2024)
Non-profit (1637)
North Carolina (122)
Northern California (187)
Obesity (49)
Opinion (45)
Pennsylvania (134)
People (17337)
Phase I (5192)
Phase II (9990)
Phase III (9455)
Pipeline (35)
Policy (23)
Postmarket research (1203)
Preclinical (1875)
Press Release (29)
Rare diseases (33)
Real estate (1402)
Recruiting (22)
Regulatory (5516)
Research institute (899)
Resumes & cover letters (81)
South America (373)
Southern California (176)
Startups (1200)
Texas (42)
United States (1904)
Vaccines (209)
Washington State (94)
Weight loss (41)
Date
Today (39)
Last 7 days (178)
Last 30 days (554)
Last 365 days (9099)
2024 (6383)
2023 (9760)
2022 (13255)
2021 (14813)
2020 (14301)
2019 (13759)
2018 (10628)
2017 (9760)
2016 (9356)
2015 (11019)
2014 (7555)
2013 (5950)
2012 (6396)
2011 (6745)
2010 (5808)
174,117 Results for "boehringer mannheim group".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Phase III
Boehringer Aces Phase III Pulmonary Fibrosis Trial, Plans FDA Application
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and inflammation in the lungs, met its primary endpoint in a late-stage study.
September 17, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
September 16, 2024
·
6 min read
Biosimilars
Boehringer Ingelheim Partners With GoodRx to Offer Humira Biosimilar at 92% Discount
In a bid to take advantage of Humira’s slow loss of market share, Boehringer Ingelheim is offering its biosimilar at a 92% discount exclusively to patients who buy the product on GoodRx.
July 19, 2024
·
2 min read
·
Tristan Manalac
Drug Development
MASH Clash Between Lilly and Boehringer-Zealand Takes Center Stage at EASL24
Both Eli Lilly and the partnered companies Boehringer Ingelheim and Zealand Pharma have mid-stage data readouts this week, fueling the race in metabolic dysfunction-associated steatohepatitis.
June 7, 2024
·
3 min read
·
Greg Slabodkin
Deals
Boehringer Buys Nerio Therapeutics for $1.3B to Boost Immuno-Oncology Pipeline
Under the deal announced Monday with the California biotech, German pharma Boehringer Ingelheim is gaining access to novel immune checkpoint inhibitors designed to activate the immune system to fight cancer cells.
July 29, 2024
·
2 min read
·
Tyler Patchen
Business
Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia
Boehringer Ingelheim and Sosei Group Corporation announced they have entered a global collaboration and exclusive option-to-license agreement.
March 11, 2024
·
10 min read
Business
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut.
May 16, 2024
·
3 min read
Drug Development
Boehringer, Zealand Heat Up MASH Race With Strong Phase II Data
The companies announced Friday that their candidate survodutide, which is licensed to Boehringer Ingelheim from Zealand Pharma, improved fibrosis in more than 50% of treated patients with metabolic dysfunction-associated steatohepatitis.
June 7, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
September 9, 2024
·
9 min read
Legal
Boehringer Ingelheim Loses Legal Challenge to IRA in Connecticut Federal Court Ruling
A federal judge ruled last week that the U.S. government can use its economic standing as a bulk purchaser to negotiate for better deals, handing Boehringer Ingelheim a loss in its legal challenge to the Inflation Reduction Act.
July 8, 2024
·
2 min read
·
Tristan Manalac
1 of 17,412
Next
